FDA Approves First Gene Therapy For High-Risk, Non-Muscle-Invasive Bladder Cancer

RTTNews | 1007 hari yang lalu
FDA Approves First Gene Therapy For High-Risk, Non-Muscle-Invasive Bladder Cancer

(RTTNews) - The U.S. Food and Drug Administration has approved Ferring Pharmaceuticals A/S's Adstiladrin (nadofaragene firadenovec-vncg) to treat high-risk, non-muscle-invasive bladder cancer.

Adstiladrin is a non-replicating, i.e., cannot multiply in human cells, adenoviral vector based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

It is the first gene therapy to be approved by the FDA to treat such high-risk, non-muscle-invasive bladder cancer, which is a disease in which malignant cells form a tumor in the tissues of the bladder.

According to the Centers for Disease Control and Prevention, about 57,000 men and 18,000 women are diagnosed with bladder cancer annually in the United States.

The safety and effectiveness of Adstiladrin was evaluated in a multicenter clinical study that included 157 patients with high-risk BCG-unresponsive NMIBC. Of them, 98 patients had BCG-unresponsive CIS with or without papillary tumors and could be evaluated for response.

In the trial, patients received Adstiladrin once every three months for up to 12 months, or until unacceptable toxicity to therapy or recurrent high-grade NMIBC.

Adstiladrin is administered once every three months into the bladder through a urinary catheter. Individuals who are immunosuppressed, or immune-deficient should not come into contact with Adstiladrin.

The most common adverse reactions associated with Adstiladrin included bladder discharge, fatigue, bladder spasm, urinary urgency, hematuria (presence of blood in urine), chills, fever, and painful urination.

The Adstiladrin application was granted Priority Review, Breakthrough Therapy, and Fast Track designations.

Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, "This approval provides healthcare professionals with an innovative treatment option for patients with high-risk non-muscle invasive bladder cancer that is unresponsive to BCG therapy."

For More Such Health News, visit rttnews.com

read more
Higher Open Called For Taiwan Stock Market

Higher Open Called For Taiwan Stock Market

The Taiwan stock market has alternated between positive and negative finishes through the last five trading days since the end of the eight-day winning streak in which it had surged more than 1,450 points or 5.8 percent. The Taiwan Stock Exchange now sits just beneath the 25,580-point plateau although it's expected to move back into the green again on Monday.
RTTNews | 15 minit yang lalu
Singapore Shares Overdue For Support On Monday

Singapore Shares Overdue For Support On Monday

The Singapore stock market has finished lower in six straight sessions, slumping more than 50 points or 1.2 percent along the way. The Straits Times Index now sits just above the 4,300-point plateau although it's expected to open to the upside on Monday.
RTTNews | 45 minit yang lalu
Malaysia Stock Market May Reclaim 1,600-Point Level

Malaysia Stock Market May Reclaim 1,600-Point Level

The Malaysia stock market has moved lower in two straight sessions, slipping almost 15 points or 0.9 percent in that span. The Kuala Lumpur Composite Index now sits just shy of the 1,600-point plateau although it's likely to bounce higher on Monday.
RTTNews | 1j 15min yang lalu
Japan Shares Likely To Remain Rangebound On Monday

Japan Shares Likely To Remain Rangebound On Monday

The Japanese stock market has moved lower in two of three trading days since the end of the four-day winning streak in which it had surged more than 1,430 points or 3.2 percent. The Nikkei 225 now sits just beneath the 45,050-point plateau and it may see mild upside on Monday.
RTTNews | 1j 30min yang lalu
Tech Shares May Lift South Korea Stock Market

Tech Shares May Lift South Korea Stock Market

The South Korea stock market has finished lower in two of three days since ending the 11-day winning streak in which it had surged more than 300 points or 9.6 percent. The KOSPI sits just above the 3,440-point plateau and it may tick higher again on Monday.
RTTNews | 1j 45min yang lalu
Hong Kong Inflation Data Due On Monday

Hong Kong Inflation Data Due On Monday

Hong Kong will on Monday release August figures for consumer prices, highlighting a light day for Asia-Pacific economic activity.
RTTNews | 2j 45min yang lalu
Swiss Market Ends Higher For 2nd Straight Session

Swiss Market Ends Higher For 2nd Straight Session

The Switzerland market opened on a slightly weak note on Friday, but recovered swiftly and then kept edging higher to eventually end the day's session on a firm note.
RTTNews | 2 hari yang lalu